Biotech Short Candidates Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who started this subject	5/11/2004 1:17:24 AM
From: mopgcw	of 897

I have no idea who this firm is, but from Barron's: Pozen (POZN-NYSE) by M.S. Howells (12.34, April 22) Sell/Sell Short. Pozen is somewhat unique in that it focuses on developing compounds that are comprised of older, already approved drugs....It is focused on developing compounds for the treatment of migraine and has two late-stage product candidates for this indication....Current product candidates are MT100 and MT400. MT400, an oral combination containing a triptan and a nonsteroidal anti-inflammatory, has been partnered with Glaxo and is expected to enter Phase III in late 2004. We consider MT400 Pozen's most promising product....MT100, an oral combination product containing naproxen and metoclopramide, is currently under review by the FDA and is unpartnered in the U.S. MT100 is Pozen's key near- and intermediate-term value driver and is critical to the stock over the next 45 days.... We don't believe MT100's clinical-trial results support approval. We believe the "refined" statistical analysis applied to MT100's two pivotal trials, which generated positive results from otherwise negative results in one of the trials, will be closely scrutinized by the FDA.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next